Background-Pulmonary vein isolation has increasingly been used to cure atrial fibrillation, but concerns have recently been raised that subclinical brain damage may occur because of microembolization during these procedures. We compared the occurrence of bubble formation seen on intracardiac echocardiography and the microembolic signals (MESs) detected by transcranial Doppler on the use of different ablation techniques and anticoagulation strategies. Methods and Results-This prospective study included 35 procedures in 34 consecutive patients (age, 52; SD, 12.8 years;
M anifest stroke and transient ischemic attacks are among the most fearful adverse events during transcatheter ablation for atrial fibrillation (AF), with an occurrence rate of around 1%. 1 Recent data suggest, that clinically apparent cerebral ischemia is only the "tip of the iceberg" because silent ischemic lesions can be demonstrated by diffusionweighted cerebral MRI in a much higher proportion of the patients undergoing left atrial (LA) ablation. [2] [3] [4] [5] [6] [7] Although the clinical relevance of these lesions is unknown, they raise new concerns regarding the safety of AF ablation. Importantly, a significant correlation has been demonstrated between the incidence of these cerebral lesions and the ablation technology used: circular multipolar phased radiofrequency (RF) ablation has consistently been associated with the highest incidence of new lesion formation, in up to 37% of the procedures, whereas cryoenergy seems to be the safest technique. 8 
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Real-time assessment of the thromboembolic risk during LA ablation with the potential to guide energy delivery, thereby improving procedure safety, is intriguing. To date, 2 methods have been used for this purpose: the monitoring of microbubbles on intracardiac echocardiography (ICE) and the detection of microembolic signals (MESs) in the cerebral arteries by transcranial Doppler (TCD). The titration of RF energy based on the intensity of microbubble formation during LA ablation was first proposed by Kilicaslan et al 9 and has become routine practice in many centers. Limited data are available on the number of MESs during LA ablation for AF. In a recent report, significantly more MESs were detected with the use of irrigated RF energy as compared with cryoablations, 10 confirming previous MRI findings, which suggested an ablation technology-dependent risk of nonclinical cerebral ischemia. However, currently there are no data available regarding the composition of these MESs, although multifrequency TCD has the ability to discriminate between the solid and the gaseous types. Furthermore, the distribution of MESs during the different stages of AF ablation procedures involving different types of energy and the potential influence of different anticoagulation regimes on the number of MES have not been studied yet.
The aims of the present study were, therefore, to investigate cerebral microembolization during different stages of LA ablation with a cryoballoon (CB) versus multipolar phased RF technology and the pulmonary vein ablation catheter (PVAC), and also the ratio of solid/gaseous emboli and the influence of different anticoagulation strategies on the MES burden.
Methods

Patients
Thirty-four consecutive patients undergoing pulmonary vein isolation (PVI) for symptomatic paroxysmal or persistent AF not adequately controlled by ≥1 antiarrhythmic drug were eligible for inclusion in the study. The exclusion criteria included long-standing persistent AF, hyper-and hypothyroidism, valvular heart disease, heart failure of New York Heart Association class III or IV, a left ventricular ejection fraction ≤40%, a LA diameter exceeding 50 mm, an LA thrombus, documented carotid stenosis, previous ischemic stroke or transient ischemic attacks, prior cardiac surgery or ablation in the LA, unstable angina or myocardial infarction within the last 3 months, severe chronic obstructive pulmonary disease, known bleeding disorders, and contraindication to oral anticoagulation and pregnancy. The study was approved by the local ethics committee.
After inclusion, patients were randomized into 3 different treatment groups: PVI with a CB catheter and the intraoperative administration of heparin to reach a minimum activated clotting time (ACT) level of 250 s according to the Venice Chart Consensus Protocol on Atrial Fibrillation Ablation 11 (CRYO group); PVI with the PVAC and also the conventional intraoperative anticoagulation protocol (ACT>250 s; PVAC group); and PVI performed with the PVAC using an anticoagulation protocol with an ACT target of >320 s (PVAC high-ACT group).
Patient Preparation and Ablation Procedure
Patients were hospitalized 1 or 2 days before the procedure. In patients taking oral anticoagulation, the drug was continued and the procedure was performed with an international normalized ratio in the therapeutic range. In all other patients, low-molecular-weight heparin was started twice daily in a weight-adjusted dose and administered until 12 hours before the procedure. Transesophageal echocardiography was carried out within 24 hours before the procedure to rule out the presence of a cardiac thrombus.
All procedures were performed under conscious sedation, using midazolam and fentanyl. Decapolar and quadripolar catheters were advanced from the femoral vein and positioned in the coronary sinus and the right ventricle. A single transseptal puncture was performed under fluoroscopic and ICE guidance, using a standard technique. A deflectable 12-Fr long sheath (FlexCath, Medtronic CryoCath LP, Kirkland, Quebec, Canada) was used in the LA and flushed continuously with heparinized saline at a steady rate of 30 mL/h throughout the procedure to minimize microbubble generation on ICE. This sheath was used as a guide with either the PVAC or the CB catheter. Immediately after transseptal puncture, a 150-IU/kg body weight intravenous heparin bolus was given, followed by a continuous infusion to maintain the predefined minimum target ACT level (250 or 320 s). ACT was always checked before the first ablation and every 20 minutes thereafter. Additional 2000-to 5000-IU IV boluses of heparin were administered, if needed, to reach the minimum target ACT level.
The technology of CB ablation has been described in detail. 12 A 28-mm balloon was used exclusively in all cases. The balloon was introduced into the PV ostium over the Achieve guidewire (Medtronic Ablation Frontiers, LLC, Carlsbad, CA), which is capable of mapping PV potentials before, during, and after cryo applications. Occlusion of the vein was assessed by means of a hand-held injection of contrast medium through the Arctic Front catheter. A minimum of two 5-minute freezing cycles were applied per PV. PVI was assessed on the basis of signals recorded by the Achieve wire.
The technical specifications of the PVAC and the GENius RF generator (Medtronic Inc, Minneapolis, MN) have been described in detail. [13] [14] [15] The catheter was advanced through the FlexCath sheath over a 0.032-inch guidewire, which was positioned selectively in each PV. The positions of the electrodes relative to the PV ostium were always confirmed before the first RF delivery, by means of selective contrast injection through the FlexCath sheath. The PVAC was connected to the GENius RF generator, which is capable of delivering RF current in different bipolar/unipolar mode ratios to any or all of the 5 bipolar channels in a duty-cycled mode. The target temperature was 60°C, measured separately for all bipoles. Bipolar/unipolar RF delivery was started at a ratio of 4:1 for each PV and changed to a bipolar/unipolar proportion of 2:1 or 1:1 for a deeper lesion when a sufficient reduction in local electrogram amplitude could not be achieved after multiple RF deliveries. RF energy was applied for 60 s, at least 3 to 4 times per PV. RF was delivered to all poles during initial applications at each PV. Later, usually after multiple energy deliveries, electrode pairs were selected on the bases of local electrograms. Importantly, any electrode pair that failed to reach ≥50°C during RF delivery was switched off to avoid ineffective energy delivery and thrombus formation because of improper contact at the electrode-tissue interface. Furthermore, when any electrode reached the target temperature while delivering very low power (1-2 W), it was considered a sign of an undesirably strong electrode-tissue contact or a wedge position of the electrode, and energy delivery to that particular electrode was switched off. The end point was electric isolation of all PVs, as confirmed by demonstrating an entrance block.
TCD Recording and Evaluation
TCD recording was performed throughout the whole period of LA access. The transducer was held in place by a proprietary headpiece supplied with the system. The middle cerebral arteries were bilaterally insonated from transtemporal windows by using a multifrequency Doppler (Multi Dop T digital, DWL, QL software version 2.8), which insonates simultaneously with 2-and 2.5-MHz frequencies. The system is capable of the automatic online identification of true MESs with a sensitivity of 100% and a specificity of 99.3%, 16 and also of discrimination between gaseous and solid emboli with a specificity of 96.5%. 17 The identification of true MESs with parallel artifact rejection is possible by implementing an event detector system, using a previously published algorithm to detect high-intensity signals because of emboli. 16 This step is followed by a second algorithm using data from the dual-frequency insonation to determine whether the MESs are attributed to a solid or to a gaseous embolus. Differentiation is possible because the reflection of ultrasound power is dependent not only on the size of the embolus, but also on its composition and the insonating frequency used: solid emboli reflect more ultrasound at 2 MHz than at 2.5 MHz, whereas the opposite is true for gaseous emboli.
TCD parameter settings as recommended by the consensus criteria 18 were kept constant during the procedures. The insonation depth was 45 to 55 mm, the sample volume was 8 mm, and the power was 60 to 100 mW. An example of a TCD record is given in Figure 1 .
MES counts were collected and evaluated separately during different stages of the procedure as follows:
1. Transseptal puncture: the 30-s period after crossing the interatrial septum with the transseptal needle. 2. PV angiography: contrast injection through the injection port of the CryoCath catheter or the transseptal sheath during PVAC ablation. 3. Energy delivery: from the start to 15 s after the termination of energy delivery. 4. The remainder of the procedure: that part of the LA access period during which none of the aforementioned maneuvers were performed.
ICE Monitoring
During each ablation phase, ICE was used for a semiquantitative characterization of the bubble formation by grouping them into 3 categories based on the bubble density. 9 Isolated bubbles were categorized as "few," those with a continuous but not dense appearance as "moderate," and those with a continuous and dense appearance as "shower" (Figure 2 ).
Statistical Methods
Data were derived by summing signal counts during the entire intervention, and also for the categories of each investigated factor defined by the ablation stage, whether electrodes 1 and 5 were simultaneously operating, and the bipolar-to-unipolar energy ratio. Gaseous and solid signal counts were summed (total signal count). Variables for signal count data were natural log-transformed to improve normality. Multilevel mixed-effects linear regression was used to evaluate the effects of the ablation type and the investigated factors (procedure stage, electrode 1+5 simultaneous operation, bipolar/unipolar ratio) on the total signal count. The number of models and the number of investigated factors fitted were the same, with interaction terms between the ablation type and the factor in each. The models were also adjusted for further variables found to be useful additions because of the consequential improvement of the model fit or the elimination of confounding. Fixed effects were expressed as estimated differences in the log-transformed outcome, 95% confidence intervals, and P values. Model checking was based on inspection of the normality of residuals. P values <0.05 were interpreted as indicating statistical significance. For unadjusted descriptive tables of patient clinical characteristics and procedural data, Fisher exact test was used to compare the 3 groups in terms of categorical variables: for continuous variables, appearing in these tables, and in the descriptive figure for total signal count, the assumptions regarding normality (D'Agostino test) and homoscedasticity (Levene robust test) were checked and analysis of variance was used if both were satisfied; otherwise, the Kruskall-Wallis test was applied.
We carried out post hoc power calculations based on sample sizes, means, and SDs of the primary outcome variable (total signal count) observed in all possible pairings of groups of the investigated factors, after the 2-sample comparison of means scenario (taking sample independence or paired nature into account), 2-sided test, α=0.05. Data were reduced to a single-record-per-subject structure by averaging or exclusion. We obtained for the detection of between-groups differences in relation to ablation type across all stages (power >0.9 in 2 of 3 possible pairings), ablation type in the ablation stage (power >0.9 in 2 of 3 pairings), bipolar/unipolar ratio (power >0.9 in 1 of 4 pairings, stratification for ablation type), electrode 1+5 simultaneous operation (power >0.9 in 1 of 2 pairings, same stratification), and procedure stage (power >0.9 in 11 of 18 pairings, same stratification); power figures for selected group pairings were <0.9, ranging from 0.05 to 0.89 (power >0.8 in 4 of 13 such pairings). 
Results
Patient Characteristics
A total of 34 patients who participated in 35 procedures were enrolled in this study. Table 1 presents clinical parameters of the patients in the 3 treatment groups. There were no significant differences in the baseline characteristics. 
Procedural Data
Procedural data are listed in Table 2 . The total procedure time, the total fluoro time, and the total energy delivery time were significantly longer in the CRYO group than in the PVAC groups. The mean ACT values also differed significantly in the 3 treatment groups according to the predefined protocol. No procedure-related complication was encountered in any patient.
MES Count
Because bilateral insonation of the middle cerebral arteries could not be achieved in all patients for technical reasons, MES counts were based on TCD recording of 16,22, and 23 arteries in the CRYO, PVAC, and PVAC high-ACT treatment groups, respectively. Mean MES counts per patient were calculated using either the mean of the bilateral counts when both sides were measured, or the unilateral data when only 1 side was available. As shown in Figure 3 , cerebral MES count was significantly lower in the CRYO group as compared with the 2 PVAC groups (P=0.0005). No statistical difference was found between the 2 PVAC groups at this sample size (P=0.1419).
As regards the MES count during the different stages of the procedure, a relatively even distribution of embolus formation was found across the whole LA access time with CB, whereas the embolus formation was concentrated in the energy-delivery period with PVAC (Figure 4, top) . The statistically significant difference seen in the total MES count could therefore be attributed to the difference during energy delivery (Figure 4 , bottom).
The ratios of gaseous versus solid MESs detected in the 3 treatment groups are illustrated in Figure 5 . Less than 20% of all microemboli were categorized as solid in all 3 groups. This ratio was constant across the different stages of the procedure.
Two ablation parameters potentially influencing the MES counts during the PVAC procedures were also analyzed: RF delivery with different bipolar/unipolar ratios, and the use versus the avoidance of simultaneous energy delivery on PVAC pairs 1 and 5. The latter was a significant predictor for a higher MES count in the normal-ACT PVAC group (P=0.036), but the bipolar/unipolar ratio did not influence MES formation.
Correlation Between ICE and MES Count
A significant correlation was found between bubble formation on ICE and the generation of MESs in all 3 groups during the procedure (P<0.001). The average number of MESs/min corresponding to the different grades of bubble formation on the semiquantitative ICE scale is indicated in Figure 6 . Bubble formation on ICE required a critical amount of MESs and was not sensitive to detect infrequent microembolization.
Miscellaneous Observations
A shower of bubbles on ICE mostly appeared 5 to 10 s after RF delivery had been started. The onset of the shower of bubbles was followed by bursts of MESs, usually 5 to 10 s later (Video in the online-only Data Supplement). The gradual decrease and disappearance of the MESs and bubbles was usually observed within 10 to 15 s after the termination of energy delivery (Video in the online-only Data Supplement). Catheter manipulation, especially rotation, during this period often resulted in a new burst of microemboli detected by both techniques. Switching off poles that did not reach the target temperature during RF delivery did not result in an apparent change in the degree of microembolus generation. However, in those rare instances when PVAC electrodes were dislodged from the ostium deeper into the PV, a rapid rise in temperature with low delivered power (1-2 W) was usually observed, indicating an excellent contact or a poor cooling effect from the blood. An abrupt and very marked microembolization was also observed in the majority of these cases, prompting an immediate termination of RF delivery. During CB procedures, a burst of MESs was usually observed after the balloon had deflated after the application.
Discussion
The clinical significance of silent cerebral lesions demonstrated by diffusion-weighted MRI studies 2-8 is currently unknown. Recent data indicate that the majority of them are only transient phenomena with a clear tendency to resolve within a few weeks, especially those with small diameters. 19 A potential relationship between subclinical cerebral ischemia and a longer-term deterioration in cognitive function has to be considered, although in 1 study a subtle cognitive impairment did not correlate with the appearance of new MRI lesions. 3 Although cerebral MRI studies were of utmost importance in drawing attention to the entity of subclinical cerebral ischemia, its recognition after ablation is too late for the individual patient. The real-time monitoring of embolic traffic in the brain might be a useful approach if backed up by more clinical data. Kilicaslan et al 9 first reported on the MES count detected by TCD during point-by-point pulmonary antrum isolation with the use of nonirrigated RF catheters. They demonstrated that cerebral microembolization occurs during all PVI procedures. Moreover, an unexpectedly high number of cerebral microemboli was found as compared with those seen during cardiac surgery. Additionally, a significant correlation was demonstrated between the occurrence of manifest stroke and the number of MESs detected during the ablation procedure. Importantly, that study also proved the correlation between the MES count and the degree of microbubble formation on ICE. Similar data regarding the potential clinical significance of MES generation during CB ablation have not been published. Two other studies reported on cerebral microembolization detected by TCD during different AF ablation approaches recently. 10, 20 In concordance with the MRI data, the number of MESs in these studies was dependent on the ablation technology. This is the first study to our knowledge, which has also provided data regarding the composition of these microemboli by demonstrating that the majority of them are gaseous, solid particles occurring in <20% of them, regardless of the technology and the anticoagulation scheme used. Although not supported by scientific evidence, it is a general belief that gaseous emboli are less harmful than solid particles. 21 However, with similar proportions of solid MESs in the 3 treatment groups, the absolute number is significantly higher during PVAC ablation. Although none of our patients sustained a clinical stroke or transient ischemic attacks, longitudinal assessment of the cognitive function seems justified in these patients.
We found significant differences between CB and PVAC ablation in the temporal distribution of microembolus formation throughout the whole LA access time. The even distribution with CB technology suggests that catheter manipulation, inflation, and deflation of the balloon, and contrast injections into PVs are mainly responsible for MES generation. In contrast, the majority of MESs during PVAC ablation were recorded at the time of energy delivery: microemboli usually appeared in large quantities 10 to 15 s after RF delivery had been started. Although RF delivery with different bipolar/unipolar ratios did not influence MES formation, simultaneous RF delivery on PVAC pairs 1 and 5 was a significant predictor for a higher MES count in the normal-ACT PVAC group. The likely explanation for this finding is a reduced interelectrode distance or electrode overlap because of anatomic constraint of the PVAC loop arguing for a careful assessment on fluoroscopy or even routine avoidance of simultaneous RF delivery on poles 1 and 10.
Similar to our findings, a significant correlation was reported between the quantity of MESs and the degree of bubble formation detected by ICE, 9 the latter being used as a guide for power titration. An important difference between point-by-point RF and PVAC ablation, however, is that the power cannot be adjusted with the GENius ablator; indeed, the power management is entirely automatic, with no opportunity for the operator to exert control. Similar data regarding the potential clinical significance of MES generation during CB ablation have not been published.
Several hypotheses have been put forward to explain the potential mechanism of thrombus formation with the PVAC catheter. Because PV ostia and antra are widely variable in size and shape, a good tissue contact simultaneously with all electrodes of the circular PVAC that comes only in 1 size and shape may not always be possible. Increased char formation on noncontact electrode tips and dislodgment of thrombi from the endothelium acutely damaged by RF applications during subsequent catheter rotations is a plausible explanation, which was supported by our observation that especially shortly after the termination of RF delivery, catheter manipulations often resulted in the reinitiation of MES formation. Another potential source of MES generation is tissue overheating. Tissue temperatures exceeding 80°C have been demonstrated to cause endothelial cell disruption, with the consequent loss of anticoagulation properties and heat-related denaturation of fibrinogen to fibrin, which in general might be responsible for a higher thrombogenicity of RF energy. [22] [23] [24] [25] Irrigated RF catheters have been introduced into clinical practice to reduce thrombus formation through irrigation of the ablation electrode and reduction of the electrode-endothelium interface temperature. The original concept of the PVAC catheter and the GENius ablator was that the "off" phase of RF delivery with the duty-cycled mode provided enough time for the electrodes to cool down without using irrigation, thereby preventing thrombus formation on the electrodes. However, there are as yet no definitive data on whether duty-cycled RF energy with cooling by local blood flow provides the same protection from heating-related coagulum generation as open-irrigation catheters do. The MRI studies and our findings on the MES count do not seem to validate this concept.
The use of different ACT targets for intraprocedural heparinization did not result in a statistically significant impact on the MES count in this relatively small group of patients. The potential benefit of a more aggressive anticoagulation protocol needs to be assessed in larger-scale studies, although its impact on the mostly gaseous microemboli is questionable.
Currently available recommendations for periprocedural anticoagulation during AF ablation 11 may not apply uniformly to different ablation technologies involving the use of different types of energy. Instead, procedure-specific protocols need to be elaborated to maximize patient safety.
Limitations
The sample size in this study was relatively small. Nevertheless, a marked statistical difference was found between the CB and PVAC technologies in the number of cerebral MESs. However, the roles of different intraprocedural anticoagulation regimes need to be investigated in larger patient cohorts.
Our study compared 2 single-shot technologies assumed to have the least and the most thromboembolic potential based on previous cerebral MRI data. Including open-irrigated RF ablation as the most commonly used technology seems to be also important for future comparison.
The detection of silent cerebral lesions by diffusionweighted-MRI was not included in our study because available data were consistent regarding their incidence with these ablation technologies. However, simultaneous assessment of MESs detected in the middle cerebral artery and silent lesions depicted by diffusion-weighted-MRI in other territories of the brain might have provided additional and complementary information.
We examined cerebral MES as a surrogate marker of the risk of neurological complications and did not include a clinical evaluation of the potential deleterious consequences of MESs. Assessment of subtle changes in cognitive function by comparing preoperative and postablation results should be an important aspect in future studies. Bilateral TCD recording was not possible in a minority of our patients because of technical reasons; therefore, MES counts were reported as a mean per patient. Therefore, data from patients with MES detection on 1 side have half the weight compared with those with bilateral detection. This could have potentially led to a confounding variable affecting the analysis. However, previous studies in agreement with our interim analysis have consistently shown no side differences in the number of MESs recorded by TCD.
Differentiation between solid versus gaseous microemboli was automatic. In the validation studies 16, 17 of this TCD system, gaseous and solid MESs were differentiated with 96% specificity. Furthermore, in a feasibility study performed in 10 patients with a different TCD equipment and manual counting of MESs we found a solid/gaseous microemboli ratio of 19/81, in agreement with the results obtained with automatic differentiation.
Conclusions
Cerebral microembolization was assessed by using TCD to compare AF ablation with a CB catheter versus PVAC and phased RF. In line with the results of previous MRI studies on the incidence of silent cerebral lesions, phased RF ablation was associated with significantly more MESs than CB ablation. Use of higher ACT target for intraoperative heparinization during PVAC ablation resulted in a trend to a lower MES count that did not reach statistical significance at the size of our patient cohort. Although the occurrence of MESs exhibited an even distribution during CB ablation, it was concentrated during RF delivery with phased RF technology. The majority of MESs were gaseous, regardless of the ablation technique and the phase of the procedure.
